BCL2 and rheumatoid arthritis: Metabolite analysis identified 84 active components in I. seguinii, including the discovery of luteolin, with 119 targets predicted for RA treatment, including core targets like AKT1, toll‐like receptor 4 (TLR4), epidermal growth factor receptor (EGFR), tumor necrosis factor (TNF), TP53, NFKB1, janus kinase 2 (JAK2), BCL2, mitogen‐activated protein kinase 1 (MAPK1), and spleen‐associated tyrosine kinase (SYK).